

VOLUME 25 - ISSUE 4

August 2020

ISSN: 1092-8529



Cambridge.org/cns

# CNS SPECTRUMS

EDITOR-IN-CHIEF: **STEPHEN M. STAHL**



THE JOURNAL OF THE  
**Neuroscience  
Education Institute**



**CAMBRIDGE**  
UNIVERSITY PRESS

CAMBRIDGE

# Stahl's Illustrated

Complete your collection at [cambridge.org/stahlsillustrated](http://cambridge.org/stahlsillustrated)



CAMBRIDGE  
UNIVERSITY PRESS

# CNS SPECTRUMS

## CONTENTS

### EDITORIAL

#### The use of lithium in mixed states

Gabriele Sani and Andrea Fiorillo 449

#### Revitalizing monoamine oxidase inhibitors: a call for action

P. Ken Gillman, S. Shalom Feinberg and Laura J. Fochtmann 452

### LETTER TO THE EDITOR

#### Effective use of atomoxetine to treat six inpatient youths with disruptive mood dysregulation disorder without attention deficit disorder

Xavier Benarous, Vladimir Ferrafiat, Jessica Zammit, Angèle Consoli, Priscille Gérardin, Jean-Marc Guilé and David Cohen 455

#### Commentary letter on “Revitalizing monoamine oxidase inhibitors: a call for action”

Carlo Ignazio Cattaneo, Michele Fornaro, Francesca Vittoria Ressico and Giulio Perugi 458

### REVIEW

#### Pathophysiologic mechanisms, neuroimaging and treatment in wake-up stroke

Mohamed Elfil, Mohamed Eldokmak, Alireza Baratloo, Nada Ahmed, Hardik P. Amin and Brian B. Koo 460

#### Economic burdens on parents of children with autism: a literature review

Xiaoli Liao and Yamin Li 468

#### Catatonia secondary to anti-N-methyl-D-aspartate receptor (NMDA) encephalitis: a review

Inês Marques Macedo and João Gama Marques 475

#### Antineuroinflammatory therapy: potential treatment for autism spectrum disorder by inhibiting glial activation and restoring synaptic function

Yong-Jiang Li, Xiaojie Zhang and Ya-Min Li 493

### ORIGINAL RESEARCH

#### Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies

Roger S. McIntyre, Trisha Suppes, Willie Earley, Mehul Patel and Stephen M. Stahl 502

#### I think, therefore I forget – using experimental simulation of dementia to understand functional cognitive disorders

Laura McWhirter, Brendan Sargent, Craig Ritchie, Jon Stone and Alan Carson 511

#### Compulsivity is measurable across distinct psychiatric symptom domains and is associated with familial risk and reward-related attentional capture

Lucy Albertella, Samuel R. Chamberlain, Mike E. Le Pelley, Lisa-Marie Greenwood, Rico S.C. Lee, Lauren Den Ouden, Rebecca A. Segrave, Jon E. Grant and Murat Yücel 519

#### Overlapping features between social anxiety and obsessive-compulsive spectrum in a clinical sample and in healthy controls: toward an integrative model

Barbara Carpita, Dario Muti, Alessandra Petrucci, Francesca Romeo, Camilla Gesi, Donatella Marazziti, Claudia Carmassi and Liliana Dell'Osso 527

#### Efficacy of trial-based cognitive therapy, behavioral activation and treatment as usual in the treatment of major depressive disorder: preliminary findings from a randomized clinical trial

Curt Hemanny, Clara Carvalho, Nina Maia, Daniela Reis, Ana Cristina Botelho, Dagoberto Bonavides, Camila Seixas and Irismar Reis de Oliveira 535

#### Criterion-related validity in a sample of migraine outpatients: the diagnostic criteria for psychosomatic research

Fiammetta Cosci, Andrea Svicher, Sara Romanazzo, Lucia Maggini, Francesco De Cesaris, Silvia Benemei and Pierangelo Geppetti 545

#### Pregabalin augmentation for resistant obsessive-compulsive disorder: a double-blind placebo-controlled clinical trial

Arash Mowla and Mehrnoosh Ghaedsharaf 552

#### Understanding the severity of depression: do nondepressive symptoms influence global ratings of depression severity?

Mark Zimmerman, Caroline Balling, Iwona Chelminski and Kristy Dalrymple 557

**Editor-in-Chief**

Stephen M. Stahl, Adjunct Professor of Psychiatry at the University of California San Diego, USA;  
Honorary Visiting Senior Fellow at the University of Cambridge, UK.

**Field Editors**

Bernardo Dell'Osso, University of Milan, Italy  
Kostas N. Fountoulakis, Aristotle University of Thessaloniki, Greece  
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA  
Donatella Marazziti, University of Pisa, Italy  
Humberto Nicolini, National Institutes of Health, Minister of Health, Mexico  
Stefano Pallanti, University of Florence, Italy  
Thomas E. Schlaepfer, University Hospital Bonn, Germany  
Frank I. Tarazi, Harvard Medical School, USA  
Carlos A. Zarate, National Institute of Mental Health, USA

**Deputy Editor**

Thomas L. Schwartz, SUNY Upstate Medical University at Syracuse, USA

**Editorial Board**

Leslie Citrome, New York Medical College, USA  
Christoph U. Correll, Hofstra Northwell School of Medicine, USA  
Maria Conceição do Rosario, University of São Paulo Medical School, Brazil  
Jeffrey L. Cummings, Cleveland Clinic, USA  
Thilo Deckersbach, Harvard Medical School, USA  
Bernardo Dell'Osso, University of Milan, Italy  
Koen Demyttenaere, University Psychiatric Center KuLeuven, Belgium  
Karen D. Ersche, University of Cambridge, UK  
Nesrin Dilbaz, Üsküdar University NP Brain Hospital, İstanbul  
Gianni Faedda, The Mood Disorders Center of New York, USA  
Robert L. Findling, Virginia Commonwealth University, USA  
Patrick R. Finley, University of California, San Francisco, USA  
Kostas N. Fountoulakis, Aristotle University of Thessaloniki, Greece  
Mark S. George, Medical University of South Carolina, USA  
Ira D. Glick, Stanford University, USA  
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA  
Jon Grant, University of Chicago, USA  
Gregor Hasler, University of Berne, Switzerland  
Eric Hollander, Albert Einstein College of Medicine and Montefiore Medical Center, USA  
Daphne Holt, Harvard Medical School, USA  
Oliver Howes, King's College, London, UK  
Peter B. Jones, University of Cambridge, UK  
Andres M. Kanner, University of Miami, USA  
Antony D. Loebel, New York University School of Medicine, USA  
Donatella Marazziti, University of Pisa, Italy  
Roger McIntyre, University of Toronto, Canada  
Herbert Y. Meltzer, Northwestern University, USA  
Philip Mitchell, University of New South Wales, Australia  
Mary Moller, Pacific Lutheran University and Northwest Integrated Health, USA  
Mark Muse, Muse Psychological Associates, USA  
Humberto Nicolini, National Institutes of Health, Minister of Health, México  
Andrew A. Nierenberg, Harvard Medical School, USA  
Stefano Pallanti, University of Florence, Italy  
Katharine A. Phillips, Weill Cornell Medical College, USA  
Diego A. Pizzagalli, Harvard Medical School, USA  
Mark H. Pollack, Rush University Medical Center, USA  
Mark H. Rapaport, Emory University, USA  
Irismar Reis de Oliveira, Universidade Federal da Bahia, Brazil  
Trevor W. Robbins, University of Cambridge, UK  
Peter P. Roy-Byrne, University of Washington School of Medicine, USA  
Barbara J. Sahakian, University of Cambridge, UK  
Gerard Sanacora, Yale University School of Medicine, USA  
Alan F. Schatzberg, Stanford University School of Medicine, USA  
Thomas E. Schlaepfer, University of Bonn, Germany  
Thomas L. Schwartz, SUNY Upstate Medical University in Syracuse, USA  
Erich Seifritz, University of Zürich, Switzerland  
Jordan W. Smoller, Harvard Medical School, USA  
Dan J. Stein, University of Cape Town (UCT), South Africa  
Stephen Strakowski, University of Texas at Austin, USA  
T. Scott Stroup, Columbia University, USA  
Frank I. Tarazi, Harvard Medical School, USA  
Michael E. Thase, University of Pennsylvania, USA  
Michael Trimble, National Hospital for Neurology, Queen Square, London  
Madhukar H. Trivedi, University of Texas Southwestern Medical Center, USA  
Hiroyuki Uchida, Keio University School of Medicine, Japan  
Susan Velasquez, California Department of State Hospitals, USA  
Benedetto Vitiello, University of Turin, Italy  
Karen Dineen Wagner, The University of Texas Medical Branch, USA  
Katherine D. Warburton, California Department of State Hospitals, USA  
Stephen R. Wisniewski, University of Pittsburgh, USA  
Carlos A. Zarate, Jr., National Institute of Mental Health, USA  
Joseph Zohar, Tel Aviv University, Israel

**Managing Editor**

Lisa Arrington, Cambridge University Press (larrington@cambridge.org)

## Aims and Scope

*CNS Spectrums* covers all aspects of the clinical neurosciences, neurotherapeutics and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry.

## Submitting Manuscripts to *CNS Spectrums*

All submissions to *CNS Spectrums* should be prepared in accordance with the instructions for authors and in the style of the Journal. Manuscripts should be submitted through the dedicated *CNS Spectrums* ScholarOne Manuscripts website: <http://mc.manuscriptcentral.com/cnsspectr>

*CNS Spectrums* will consider and encourage the following types of articles for publication: **Reviews**—The review article is a comprehensive article summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; **Perspectives**—The perspective article is a type of review that is a short, focused summary of a single recent advance, a sort of spotlight on the topic, which could be for example, a single point hypothesis or a novel model. It can stimulate debate and new research. **Meta-guidelines**—A meta-guideline is a “guideline of guidelines” put together by several leading figures in a field in which there are multiple competing guidelines that require synthesis and updating; **Original Research**—Reports the results of a clinical study and contains original research; the journal will also include **Brainstorms** and **Editorials** that shall be commissioned or written by the Editor-in-Chief.

## Instructions for Contributors

The Instructions for Contributors are available on the Cambridge Journals Online web site at: <http://journals.cambridge.org/CNSifc>

## Indexing

*CNS Spectrums* is indexed by *Index Medicus*/MEDLINE and Web of Science (Thomson Reuters) as well as appearing in the annual Journal Citation Report. Introduced in 1996, the journal was acquired in whole by Cambridge University Press in November of 2011.

## Subscriptions

Institutional print and electronic: £574/\$910; Institutional electronic only: £436/\$697.

### © Cambridge University Press 2020. All rights reserved.

No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: <http://www.cambridge.org/rights/permissions/permission.htm>. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center <http://www.copyright.com>, email: [info@copyright.com](mailto:info@copyright.com).

Rights & permissions requests can be applied for online within each article by clicking “Request Permissions” within the table of contents or in the fulltext version of a specific article. Requests will be processed via the CCC Rightslink system and processed immediately.

*CNS Spectrums* (ISSN: Print 1092-8529; eISSN: 2165-6509) is published bimonthly by Cambridge University Press.

## Postmaster

Send address changes in the U.S.A., Canada, and Mexico to *CNS Spectrums*, Cambridge University Press, Journals Dept., One Liberty Plaza, 20th Floor, New York, NY 10006, U.S.A. Send address changes elsewhere to *CNS Spectrums*, Cambridge University Press, University Printing House, Shaftesbury Road, Cambridge CB2 8BS, England.

## Online availability

*CNS Spectrums* is hosted on the Cambridge Core service at [cambridge.org/cns](http://cambridge.org/cns)

Institutional subscribers: Access to full-text articles online is only granted to subscription options offering an online component. Subscriptions must be activated by the purchasing institution using the instructions provided at the time of purchase; see information for subscribers at: <http://journals.cambridge.org/>

## Reprint and Advertising Sales

Inquiries for bulk reprint sales should be sent to [USReprints@cambridge.org](mailto:USReprints@cambridge.org). Advertising inquiries should be sent to M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009; Phone: 856-768-9360; Fax: 856-753-0064; Email: [mjmrvica@mrvica.com](mailto:mjmrvica@mrvica.com).